Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 553 | 92 | 414 |
| Samples | 326 | 67 | 235 |
| Peptides | 211 | 40 | 178 |
Function
LCTL · Lactase like
This gene encodes a member of family 1 glycosidases. Glycosidases are enzymes that hydrolyze glycosidic bonds and are classified into families based on primary amino acid sequence. Most members of family 1 have two conserved glutamic acid residues, which are required for enzymatic activity. The mouse ortholog of this protein has been characterized and has a domain structure of an N-terminal signal peptide, glycosidase domain, transmembrane domain, and a short cytoplasmic tail. It lacks one of the conserved glutamic acid residues important for catalysis, and its function remains to be determined (PMID: 12084582). Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jun 2013].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 202 amino-acid changes on canonical ENST00000341509 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in LCTL · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in LCTL – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Endometrial Carcinoma | 2/42 5% | 18/612 3% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Biliary Tract Carcinoma | 0/54 0% | 23/950 2% |
| Acute Myeloid Leukemia | 2/90 2% | 0/0 0% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Melanoma | 5/210 2% | 35/1899 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 12/810 1% |
| Non-Small Cell Lung Carcinoma | 12/304 4% | 13/1390 1% |
| Colorectal Carcinoma | 13/143 9% | 33/3239 1% |
| Other Solid Cancers | 2/94 2% | 15/1515 1% |
| Germ Cell Tumour | 1/25 4% | 1/169 1% |
| Gastric Carcinoma | 0/74 0% | 18/1809 1% |
| Ovarian Carcinoma | 0/109 0% | 10/998 1% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Hepatocellular Carcinoma | 2/46 4% | 16/2210 1% |
| Bladder Carcinoma | 0/58 0% | 7/956 1% |
| Plasma Cell Myeloma | 2/44 5% | 0/305 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 11/2550 0% |
| Cervical Carcinoma | 0/35 0% | 2/422 0% |
| Breast Carcinoma | 6/144 4% | 9/3264 0% |
| Glioma | 2/52 4% | 7/2127 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Meningioma | 0/3 0% | 1/252 0% |
| Ewings Sarcoma | 1/63 2% | 0/262 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Prostate Carcinoma | 2/13 15% | 3/2105 0% |
| Other Blood Cancers | 3/61 5% | 3/2725 0% |
| Head and Neck Carcinoma | 0/85 0% | 3/1574 0% |
| Pancreatic Carcinoma | 2/89 2% | 1/1611 0% |
Mutation Distribution
Where LCTL is mutated · all tissues, split by cell line vs tissue
How many mutations in LCTL were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 553 mutations in LCTL
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|